Navigation Links
Takeda to Create Global Centers of Excellence
Date:3/30/2009

CSO will be based in the United States at Takeda's Deerfield, Illinois headquarters and in Osaka, Japan.

Dr. Ohkawa is a member of the Takeda Board of Directors and previously was the General Manager of the Pharmaceutical Research Division. Dr. Ohkawa has been with Takeda for 30 years.

Hiroyuki Odaka, Ph.D., will replace Dr. Ohkawa as General Manager, Pharmaceutical Research Division. Dr. Odaka joined Takeda in 1982 and most recently has been Director of Pharmacology Research Laboratory 1.

Tetsuo Miwa, Ph.D. will become General Manager, CMC Center. Dr. Miwa joined Takeda in 1985 and has held a number of leadership roles in Takeda's research organization, including Director of Discovery Research Center. Most recently, Dr. Miwa belonged to Strategic Product Planning and was in charge of cross-franchise portfolio management and the Millennium acquisition and transition.

Nancy Joseph-Ridge, M.D., will replace Dr. Masaomi Miyamoto as General Manager, Pharmaceutical Development Division. Dr. Joseph-Ridge is currently President of Takeda Global Research & Development Center, Inc., U.S., and will retain this position until her replacement has been announced. She was previously with TAP Pharmaceutical Products Inc.

Yoichi Okumura, will continue in his role as General Manager of Intellectual Property Department. Mr. Okumura joined Takeda in 1984 and has been General Manager of IP Department since 2007.

To ensure further global optimization of the company's pharmaceutical development functions, the global development headquarter functions will be moved to Takeda's Deerfield, Illinois headquarters in the United States, with the transfer anticipated to be complete by July 1. Previously, the Takeda Group's headquarters for development were based in Osaka, Japan, and Takeda managed global development through its regional hubs in Japan, the United States, Europe and a recently est
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Takeda Receives New Information on Alogliptin (SYR-322) NDA
2. Healthcare Businesswomens Association Announces 2009 Woman of the Year, Dr. Deborah Dunsire, President and CEO of Millennium: The Takeda Oncology Company
3. Welvista Announces Partnering with Takeda to Provide Medication at No Cost to the Uninsured
4. Review of Takedas Febuxostat New Drug Application Continues Past PDUFA Date
5. FDA Adds Three Months to Review of Takedas New Drug Application for TAK-390MR
6. Takedas investigational PPI TAK-390MR demonstrated higher healing rates compared to lansoprazole
7. Takeda Completes Acquisition of Millennium
8. Takeda Commences Cash Tender Offer for all Outstanding Shares of Millennium
9. Takeda, Abbott Announce Plans to Conclude TAP Joint Venture
10. Takeda Announces New U.S. Leadership
11. Takeda submits new drug application for alogliptin (syr-322) in the US
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... T.E.N., a technology and information ... that William H. Murray, renowned author and industry ... Leadership Award winner. Presented annually, the ISE® Luminary ... leader and industry practitioner for his or her ... information security industry. , Formerly with IBM, Murray ...
(Date:10/20/2014)... October 20, 2014 Zereana Jess-Huff, a 34-year-old ... Maryland 2014 on a platform to think outside the bra. ... uses her position to raise awareness about women’s other lady ... breast cancer. You say the color pink and everybody knows ... for a fact that it has not been won when ...
(Date:10/20/2014)... My Clients Plus ( http://www.MyClientsPlus.com ) today announced ... module enables easy administration and routing of follow-up items ... This application allows users such as Therapists to assign ... item to a specific client, categorize tasks the way ... for follow-ups. It's designed to enable easy access ...
(Date:10/20/2014)... Diego, CA (PRWEB) October 20, 2014 AttorneyOne.com, ... all the latest information from the FDA on Sit ... on October 10 not to purchase or use Sit and ... Sit and Slim II is promoted as weight loss product ... Sibutramine, removed from the market in 2010 for safety reasons, ...
(Date:10/20/2014)... Rockynol Retirement Community broke ground ... The $11 million project will include the latest in ... with full-service restaurant style dining. , “We are excited ... Assisted Living apartments,” said Kara Hanzie, Rockynol Executive Director ... of care and this investment is proof of our ...
Breaking Medicine News(10 mins):Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 2Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 4Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 2Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 3Health News:My Clients Plus Announces New Workflow Management Software 2Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Rockynol Retirement Community Expands Assisted Living Center 2
... variations that point to spectrum disorders , TUESDAY, March ... for brain proteins that seem to be linked to ... of the most comprehensive genetic analyses of association between ... spectrum disorder] risk," said Anthony Monaco, of the Wellcome ...
... ... Detox Protocol using Far Infrared. FIR therapy is a major key for returning us back ... ... Ph.D., RIET-1, a Doctor of Integrative Medicine and an Industrial Toxicologist, has dedicated a ...
... complications, costs, , TUESDAY, March 30 (HealthDay News) -- Current ... age 45, especially for those who are overweight, but new ... 30 and 45 for everyone . , When screening ... every year to five years, the average cost per quality-adjusted ...
... lung cancer per year in Germany are due to ... in the current edition of Deutsches rzteblatt International ... and his coauthors ( Dtsch Arztebl Int 2010; ... the results of relevant studies, the recently published S1 ...
... One in three South Asian, West Asian or Arab women ... say they have trouble accessing a doctor to address ... findings, from a new study by researchers at St. Michael,s ... finds this group and immigrant women and men are at ...
... ... Misunderstandings about proper use of antibiotics have the potential to ... report in the April issue of AJIC: American Journal of Infection ... Control and Epidemiology, Inc. (APIC). esearchers from Columbia University and MixedInk ...
Cached Medicine News:Health News:Scientist, Dr Staninger, Unlocks the Mystery of Morgellons Disease 2Health News:Scientist, Dr Staninger, Unlocks the Mystery of Morgellons Disease 3Health News:Diabetes Screening Should Start Sooner 2Health News:Diabetes Screening Should Start Sooner 3Health News:Minority women least likely to gain access to a doctor, study says 2Health News:Misinformation About Antibiotics Can Travel to Large Audience Via Twitter: Study 2Health News:Misinformation About Antibiotics Can Travel to Large Audience Via Twitter: Study 3Health News:Misinformation About Antibiotics Can Travel to Large Audience Via Twitter: Study 4Health News:Misinformation About Antibiotics Can Travel to Large Audience Via Twitter: Study 5
(Date:10/20/2014)... 2014 Valeritas, Inc., a leader in simple, ... Type 2 diabetes, announced today that it has received ... award was presented October 16 th at Cardinal,s ... . The Cardinal Health Supply ... of metrics specifically targeted at the importance of developing ...
(Date:10/20/2014)...  AnaptysBio, Inc., a leader in the discovery ... appointment of Marco Londei , M.D. as ... preclinical and clinical development of AnaptysBio,s proprietary antibody ... welcome Dr. Londei to AnaptysBio,s executive leadership team," ... Executive Officer of AnaptysBio. "Dr. Londei,s extensive expertise ...
(Date:10/20/2014)... Lpath, Inc. (NASDAQ: LPTN ... official notification from the European Patent Office that ... supporting its iSONEP™ and ASONEP™ programs. ... 2087002, claims compositions of matter related to sonepcizumab, ... iSONEP and ASONEP. Sonepcizumab is an antibody that ...
Breaking Medicine Technology:Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 2Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 3AnaptysBio Appoints Dr. Marco Londei to Newly Created Chief Development Officer Position Clinical Immunologist to Lead AnaptysBio's Pipeline Advancement 2Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 2Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 3Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 4
... ... ... ... ...
... ... ... ... ...
Cached Medicine Technology:KAPIDEX(TM) (dexlansoprazole) Renamed DEXILANT(TM) in U.S. to Avoid Name Confusion 2KAPIDEX(TM) (dexlansoprazole) Renamed DEXILANT(TM) in U.S. to Avoid Name Confusion 3KAPIDEX(TM) (dexlansoprazole) Renamed DEXILANT(TM) in U.S. to Avoid Name Confusion 4KAPIDEX(TM) (dexlansoprazole) Renamed DEXILANT(TM) in U.S. to Avoid Name Confusion 5KAPIDEX(TM) (dexlansoprazole) Renamed DEXILANT(TM) in U.S. to Avoid Name Confusion 6STELARA(TM) and REMICADE(R) Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting 2STELARA(TM) and REMICADE(R) Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting 3STELARA(TM) and REMICADE(R) Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting 4STELARA(TM) and REMICADE(R) Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting 5STELARA(TM) and REMICADE(R) Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting 6STELARA(TM) and REMICADE(R) Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting 7STELARA(TM) and REMICADE(R) Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting 8STELARA(TM) and REMICADE(R) Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting 9STELARA(TM) and REMICADE(R) Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting 10STELARA(TM) and REMICADE(R) Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting 11STELARA(TM) and REMICADE(R) Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting 12STELARA(TM) and REMICADE(R) Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting 13STELARA(TM) and REMICADE(R) Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting 14STELARA(TM) and REMICADE(R) Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting 15STELARA(TM) and REMICADE(R) Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting 16STELARA(TM) and REMICADE(R) Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting 17
... automated, random access immunoassay ... assays available worldwide. thyroid, ... therapeutic drug, serology, anemia ... be performed on a ...
... The Dimension Xpand integrated chemistry ... very compact footprint to the ... innovation and integration, the Dimension ... state-of-the-art Dimension technology, specifically tailored ...
... integrated systems combine the ease of use ... of the Multiply and Quicklyte integrated multisensors ... to meet the challenges of your laboratory. ... the systems can meet over 97% of ...
... SkanWasher 400 is an ... washer with built-in pressure ... individual pressure settings allow ... gentle wash to a ...
Medicine Products: